Although harmful in large quantities, hydrogen sulfide may ameliorate the health consequences of aging when small doses are applied to the mitochondria.
A team of industry and academic researchers developed a new way to engineer the immune
system, leading to the first clinical trial using genetically modified macrophages.
A new form of brain stimulation treatment that responds to a patient’s brain activity could be life changing for people with neurological and psychiatric disorders.
Usually thrown away as waste, menstrual blood may help clinicians non-invasively monitor and diagnose a multitude of health conditions from diabetes and endometriosis to cancer.
Cancer
research dominates nearly every section of our newspaper and other news vehicles. That’s why we decided to launch our latest news division, the ddn Cancer
Research Portal, your gateway to the latest oncology news, trends and resources.
Out of all of our print and
online news coverage, we have picked five stories that we feel illustrate some high points and show how ddn is unique in reporting industry news
It’s difficult to believe we’re about to put our final issue of
2011 to press, but as we don our gay apparel, pour some celebratory eggnog and give this edition a final polish, we have a rare few moments to pause and
reflect on another editorial year gone by.
There’s a facelift for ddn
beginning in December, and some new directions for coverage going into 2013. With regard to that and more, the magazine’s chief editor, Amy Swinderman, walks
you through some of the highlights of the past year and what’s in store for the future
Today, Drug
Discovery News announces the debut of the ddn Cancer Research Portal, your gateway to the latest oncology news, trends and resources. Read on to find out
what features are available on this news portal and to experience it for yourself.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.